Compare HOFT & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | KLRS |
|---|---|---|
| Founded | 1924 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 117.1M |
| IPO Year | 1999 | N/A |
| Metric | HOFT | KLRS |
|---|---|---|
| Price | $12.09 | $4.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 22.0K | ★ 85.4K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.62 | $2.14 |
| 52 Week High | $15.99 | $11.88 |
| Indicator | HOFT | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 31.92 |
| Support Level | $11.97 | $3.49 |
| Resistance Level | $13.63 | $5.43 |
| Average True Range (ATR) | 0.78 | 0.36 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 10.00 | 4.63 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.